Validating the concept of mutational signatures with isogenic cell models. by Zou, Xueqing et al.
ARTICLE
Validating the concept of mutational signatures
with isogenic cell models
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The diversity of somatic mutations in human cancers can be decomposed into individual
mutational signatures, patterns of mutagenesis that arise because of DNA damage and DNA
repair processes that have occurred in cells as they evolved towards malignancy. Correlations
between mutational signatures and environmental exposures, enzymatic activities and
genetic defects have been described, but human cancers are not ideal experimental systems
—the exposures to different mutational processes in a patient’s lifetime are uncontrolled and
any relationships observed can only be described as an association. Here, we demonstrate
the proof-of-principle that it is possible to recreate cancer mutational signatures in vitro using
CRISPR-Cas9-based gene-editing experiments in an isogenic human-cell system. We provide
experimental and algorithmic methods to discover mutational signatures generated under
highly experimentally-controlled conditions. Our in vitro findings strikingly recapitulate
in vivo observations of cancer data, fundamentally validating the concept of (particularly)
endogenously-arising mutational signatures.
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The concept of mutational signatures was postulated in2012: The catalogue of somatic mutations uncoveredthrough tumour sequencing is the outcome of one or more
mutational processes that have been operative through the life-
time of a cancer patient1,2. Each mutational process, defined by
DNA damage and DNA repair components, leaves a character-
istic pattern or mutational signature on the tumour genome1–4.
The final mutational portrait of each patient’s cancer is
determined by the intensity and duration of exposure to each
mutational process4,5.
As an analytical principle, mutational signatures have gained
considerable traction, and are regularly featured in cancer
genomics literature6–8. Already, there are multiple algorithms to
extract mutational signatures5,9–12, though each has its own
mathematical idiosyncrasies leading to results that are broadly
similar, but never identical. This has caused some to question the
robustness of the concept. Nevertheless, as a field, mutational
signature research has progressed remarkably. Mutational
signatures have been sought across tens of thousands of cancers,
revealing over 40 different base substitution signatures (paper in
preparation), further supplemented by assessments of how these
signatures are distributed across various genomic architectures
including replication-timing domains, replication strands,
nucleosome occupancy and transcription factor binding sites13,14.
More recently, genome rearrangement signatures have been
unveiled, assisting in the categorization of breast cancer
subtypes13,15,16 and clinical applications based on mutational
signatures are currently being developed17.
No matter how sophisticated the analyses of in vivo muta-
genesis of cancers, there are limitations to studying tumours—it is
an uncontrolled and noisy system18–21, and even the best clinical
metadata collections will at most, provide associations. Critics of
the concept have highlighted that this purely mathematically-
based idea, although compelling, lacks definitive validation
through in vitro methods.
Historic TP53 and HPRT reporter assays and experiments
exposing mouse embryonic fibroblasts (MEFs) to various
exogenous agents have already provided convincing evidence that
mutation patterns can be generated, particularly for environ-
mental agents such as ultraviolet light and tobacco carcino-
gens22,23. Yet, there have been limited efforts to demonstrate
similarly clear relationships for endogenous mutational processes.
Few would dispute that substitution Signature 1 composed
primarily of C>T transitions at an NpCpG sequence context is
linked with deamination of methyl-cytosines, and substitution
Signatures 2 and 13 characterised by the distinctive C>T transi-
tions and C > G transversions at a TpCpN trinucleotide context
are initiated by the activity of the APOBEC family of enzymes3,4.
However, many of the mutational signatures that are likely to be
endogenous in origin have not been verified. Associations of
specific substitution and insertion/deletion (indel) signatures with
mismatch repair (MMR) deficiency24–26, as well as substitution,
indel and rearrangement signatures with homologous recombi-
national (HR) repair deficiency27–30 though conspicuous, have
not been confirmed. Many other genes are also involved in the
myriad DNA repair pathways in our cells, and it is not clear
whether genetic defects in alternative, related genes could
produce mutational signatures as well. Even if mutational
signatures could be reproduced using in vitro techniques, it is not
known whether these signatures would mimic what is observed
in vivo.
Here, we explore whether targeted CRISPR-Cas9-based31–33
knockouts of selected DNA repair genes can recreate mutational
signatures. We describe the experimental cell-based system and
develop the computational methodologies to confirm or refute
whether each gene knockout generates mutation patterns, thus,
providing a general approach for exploring mutational signatures.
We further seek whether experimentally-generated mutation
patterns bear similar appearances and/or behaviours to
mutational signatures seen in primary cancers. If so, this would
serve to endorse that mutational signatures are not simply
mathematical extractions, but are the consequences of true
biological processes.
Results
Generation of DNA repair gene knockouts. We used the
immortalised human near-haploid cell line HAP1 to generate
isogenic CRISPR-Cas9-mediated knockouts34. The advantage of
using a haploid cell line is that CRISPR-Cas9-mediated editing is
simplified because only one genetic allele needs to be altered to
generate a null phenotype. Moreover, because only half the
genomic DNA is present, next generation sequencing (NGS)
needs are substantially reduced making the experiment more
affordable. To determine whether we could detect mutational
signatures that result from defects in DNA repair pathways we
chose to target genes that play diverse and independent roles in
the detection, signalling or repair of DNA damage (Table 1).
Aliquots of the HAP1 cell line were exposed to constructs that
express the endonuclease Cas9 and guide RNAs (gRNAs) that
were designed to target individual genes of interest. Single clones
were selected and those carrying a frame-shift mutation in the
given gene were designated as the parental cell line (Fig. 1a),
which were amplified and analysed by high-depth whole genome
Table 1 List of DNA repair genes targeted and their functions
Gene
symbol
Gene name Function Repair pathway Position
CHK2 Checkpoint kinase 2 Serine threonine kinase Cell cycle and apoptotic regulation in response to
DNA damage
22q12.1
EXO1 Exonuclease 1 5′ to 3′ exonuclease; RNase H activity Homologous recombination; mismatch repair 1q43
FANCC Fanconi anemia,
Complementation group C
Component of Fanconi repair system
core complex
DNA cross-link repair 9q22.32
MSH6 MutS homolog 6 Mismatch recognition Mismatch repair 2p16.3
NEIL1 Endonuclease VIII-like 1 DNA glycosylase and apurinic/
apyrimidinic lyase
Base excision repair 15q24.2
NUDT1 Nudix hydrolase 1 Hydrolyzes oxidized purine nucleoside
triphosphates
Modulation of nucleotide pools 7p22.3
POLB DNA polymerase beta DNA polymerase (catalytic subunit) Base excision repair 8p11.21
POLE DNA polymerase epsilon DNA polymerase (catalytic subunit) Nucleotide excision repair and mismatch repair 12q24.33
POLM DNA polymerase mu DNA polymerase (catalytic subunit) Gap filling during non-homologous end-joining 7p13
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sequencing (WGS). The parental cell lines (labelled as ‘parental
clone’ in Fig. 1a) were subsequently cultured for one month, from
which seven ‘subclones’ were derived, amplified and analysed by
WGS. This workflow served to allow for the identification of
mutations that occurred over approximately 36 cellular divisions,
considering that the doubling time is approximately 20 h.
Each parental clone and subclone was successfully sequenced
to ~15-fold depth. Short read sequences were aligned to the
human reference genome assembly GRCh37/hg19 and all classes
of somatic mutations were called in the parental clones
(subtracting from the primary bulk HAP1 population) and in
subclones (subtracting from the parental clones). Targeting of the
genes of interest was confirmed by identifying frameshift indels in
the relevant gene in short-read data (see Supplementary Fig. 1a
and Supplementary Data 1), and loss of protein expression was
confirmed through immunoblotting (Supplementary Fig. 1b).
Potential off-target edits were also systematically sought in an
agnostic manner, whether generating small or large (multi-kb)
insertion or deletions, and none were identified. Proliferation
rates were also determined for each knockout cell line
(Supplementary Fig. 1c). Moreover, potential off-target sites were
also searched using COSMID (http://crispr.bme.gatech.edu), a
web-based tool to identify and validate CRISPR/CAS9 off-target
sites35 (see Supplementary Data 2 for a ranked-list of potential
off-target sites of the relevant guide RNA sequences generated by
COSMID). Furthermore, we also confirmed in all subclones, that
no additional mutations were acquired in other DNA repair genes
during the early clonal expansion phase (see Supplementary
Data 3 for a list of DNA repair genes) that could affect the final
mutational signature obtained in each subclone.
Knockouts of DNA repair genes instigates mutagenesis. A level
of background mutagenesis was observed in parental clones
(average ~1200 substitutions, ~60 indels, ~6 rearrangements) and
in all subclones (Fig. 1b–d and Supplementary Figs. 2–4). Above
the background mutations, subclones associated with particular
gene knockouts also had greater numbers of specific classes of
mutations, although effect sizes were notably variable. For
example, the knockout of MSH6 was associated with a surge of
substitutions and indels. By contrast, the FANCC knockout was
associated with a possibly small increase in indels but a large
increase in rearrangements. Knockout of EXO1 appeared to cause
modest elevations of all classes of mutation (Fig. 1b–d). For each
gene knockout, a high level of consistency was observed between
all seven subclones in terms of total counts (Fig. 1b–d) and overall
patterns of mutations (Supplementary Figs. 2–4). Thus, at first
pass, it is possible to crudely discriminate between the effects of
gene knockouts through these experiments, suggesting that this is
a rational experimental system for exploring the mutational
effects conferred by defects in specific genes.
Understanding the signal-to-noise issue. There are however a
number of issues to acknowledge and resolve which are universal
to all human cell-based systems used for exploring mutagenesis.
First, the background mutagenesis was easily detectable: for
example, for base substitutions approximately 700–2000 muta-
tions were detected per colony and this comprises a distinctive
C>A/G>T substitution pattern with tallest peaks at TCT, GCA,
GCT and ACA (in decreasing order; Supplementary Fig. 2). This
ubiquitous signature shares considerable similarity with pre-
viously reported Signature 18, first observed in primary neuro-
blastoma3. Subsequently, this mutational signature was described
in breast and adrenocortical cancers. A very similar signature
(cosine similarity of 0.94 to Signature 18) has been associated
with mutations in the MUTYH gene, hinting that it is a final
outcome of a primary mutational process that could involve
oxidative damage8. Regardless, this mutational process was
effectively noise in our system, and was pervasive in parental
clones and subclones in our experiments, supporting the
possibility of it being due to DNA damage incurred during the
experimental process. Background mutagenesis was also
detectable in indels (Supplementary Fig. 3) and rearrangements
(Supplementary Fig. 4).
Second, this inescapable and abundant mutational process
contributed a very large volume of background mutagenesis,
which could complicate the detection of true mutational
signatures for each target knockout gene. The mutation signals
of various gene knockouts were highly different—some were
strong in nature while others may be considerably weaker, and
could be obscured by the overwhelming background signature.
These two issues of high noise and potentially low signal are
generic and arise in other cell-based models including induced
pluripotent stem cells (iPSCs)36, embryonic stem cells (ESCs)
(manuscript in preparation) and organoids36–38. As described
below, we thus developed methods to quantitatively and reliably
discern whether mutational signatures are present in cell-based
experimental systems in order that they may be applied to similar
approaches in the future.
Detecting mutational signatures in experimental systems. The
pervasive background signature was present in all parental clones
and subclones regardless of gene knockout. By contrast, if a gene
knockout produced a mutational signature, then the signature
should be observed in all relevant subclones and would not be
detectable (or be present at a greatly reduced level) in the parental
clone. We do however, expect some variation between subclones
and must therefore take this into consideration in the modelling.
Our aim therefore was to determine whether there is robust and
consistent divergence of subclones from parental clones, both
qualitatively (mutation spectrum) and quantitatively (mutation
count), indicative that targeting particular genes does indeed
produce mutational signatures.
To account for the limited number of samples and mutations
per sample, and the potentially limited signal-to-noise ratio, we
used a bootstrap resampling method of the 96-channel mutation
profile for all parental clones and subclones (Fig. 2 and Online
Methods for details). This provided us with distributions of
subclones and of parental clones from which reliable estimates of
the qualitative differences in mutation spectra could be calculated
(Fig. 2a; see Online Methods for details). An additional tier to
discriminate whether a gene knockout is associated with
mutagenesis came from taking mutation count into considera-
tion: an “expected” mutation density was used to deduce a p value
to detect an alteration in mutation burden for subclones of a
given gene knockout (Fig. 2b, see Online Methods for details).
Once a gene knockout was confirmed to be associated with
generating a mutation pattern, the final mutational profile (which
is a linear combination of background mutagenesis and the
gene knockout) was obtained by subtracting the background
mutagenesis from the mutational profile of the subclones
(see Online Methods).
This principle of signature discrimination (Fig. 2c) was applied
to indel and rearrangement patterns as well, although different
classifications were used. For indels, a vector of eight features was
used comprising the following categories: 1 bp insertion, >=2 bp
insertion, 2 bp microhomology-mediated deletion, >= 3 bp
microhomology-mediated deletion, 1 bp repeat-mediated
deletion, >=2 bp repeat-mediated deletion, other deletion (where
there are no specific junctional features associated) and complex
indels. For rearrangements, a vector of ten features was applied
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Fig. 1 Knockouts of DNA repair genes instigate mutagenesis. a The experimental strategy for investigating whether DNA repair gene knockouts produced
mutagenic effects. Parental HAP1 cells are split into multiple aliquots and used for CRISPR-Cas9-mediated gene-editing of the indicated genes. Resulting
clones carrying frame-shift mutations are identified by Sanger sequencing and immunoblotting, amplified, cultured for one month (approximately 36
divisions), and seven subclones are derived through a single-cell bottleneck. DNA is extracted and whole genome sequenced for the seven subclones, and
the parental clone. De novo mutations in a subclone that is subject to a particular knockout can be obtained by removing mutations in the parental clone
from mutations in the subclone. De novo mutations are identified for all classes of mutation: b substitutions, c indels and d rearrangements, of the seven
subclones for each knockout gene
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comprising: 1–10 kb, 10 kb–1Mb and >1Mb size groups of the
three classes of deletions, inversions and tandem-duplications,
and the last category was translocations.
By using these methods, we conclusively identified seven
mutational signatures from nine gene knockouts in this HAP1-
based experimental system: two substitution signatures were
induced by knockouts of EXO1 and MSH6 (Fig. 3); three indel
signatures produced by knockouts of EXO1, FANCC and MSH6
(Fig. 4); and two rearrangement signatures associated with
knockouts of EXO1 and FANCC (Fig. 5), as described in detail
below.
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Experimentally-generated gene knockout mutational
signatures. MSH6 is a protein involved in DNA MMR. MSH6
forms a heterodimer with MSH2 and helps to maintain a low
error rate during replication39. Inherited mutations in this gene
are associated with elevated risks particularly of colorectal and
endometrial cancer40,41. Inherited and somatic mutations with
loss of the wild-type allele are associated with elevated mutation
rates in primary human cancers, particularly at polynucleotide
repeat tracts conferring a diagnostic phenotype called micro-
satellite instability (MSI)26. In-keeping with previous observa-
tions, the MSH6 knockout was associated with considerably
elevated substitution density (~4 fold) over background and had a
characteristic pattern dominated by C>T and T>C mutations
(Fig. 3a, d). This mutational signature bears a resemblance to the
multiple substitution signatures (extracted from many different
tumour-types) that have been associated with MMR deficiency in
cancers (Signatures 6, 12, 14, 15, 20 and 26), but was not perfectly
identical to any one of them. Interestingly, when mutational
signatures are extracted from breast cancers alone and all analyses
restricted to just this tissue-type, we find that the in vitro
signature is strikingly similar to the MMR deficiency signature in
breast cancers. This is also the case for tumour-specific signature
extractions of 52 colorectal and 44 endometrial cancers, both
being cancer-types that are associated with MSH6 mutations.
Furthermore, the MSH6 knockout had a very high level of 1 bp
deletions occurring at polynucleotide repeat tracts, with ~7 fold
more deletions than insertions overall, in-keeping with MSI
(Fig. 4a, d). Intriguingly, an MSH6 knockout in an alternative
iPSC model generated an identical signature (cosine similarity is
0.94) suggesting that in different cell lines, the signature asso-
ciated with MSH6 knockout is very stable (unpublished data).
EXO1 encodes an enzyme that functions as a 5′-3′ DNA
exonuclease as well as an endonuclease cleaving RNA on DNA/
RNA hybrids (RNase H activity)42–44. It plays a role in, and
interacts with, components of both the DNA double-strand break
repair (DSBR) and MMR45 pathways. The EXO1 knockout
resulted in a substitution signature with predominantly C>A/G>T
transversions with peaks at GCT, GCC and TCT (Fig. 3d) and
smaller contributions from C>G/G>C, C>T/G>A and T>C/A>G.
The EXO1 knockout also had an indel pattern that featured a high
percentage of 1 bp repeat-mediated deletions and a smaller
proportion of long (>=3 bp) microhomology-mediated deletions
(mm-del) (Fig. 4d). This is an example where the indel knockout
signature and background signature are qualitatively similar
(cosine similarity is 0.97, Fig. 4b) but quantitatively distinct
(Fig. 4c). Additionally, the EXO1 knockout produced a rearran-
gement signature characterised predominantly by a high
percentage (60%) of medium-to-large (10 Kb–1Mb) tandem
duplications (Fig. 5d). Knockout of EXO1 thus created multiple
signatures of all mutation classes, probably as a consequence of
EXO1 operating at the junction of several DNA repair pathways.
FANCC is a component of the Fanconi anemia (FA) DNA
repair system that functions in the processing of DNA crosslinks
that are encountered in S phase via a mechanism that ultimately
employs homologous recombination (HR)28,46,47. In-keeping
with this role, the FANCC knockout created a number of
mutational signatures that are predicted to be initiated by a DNA
double-strand break. These included a characteristic indel pattern
of long deletions (⩾3 bp in length) with microhomology observed
at the indel junction (Fig. 4d). Furthermore, the FANCC
knockout produced a rearrangement pattern characterised by
chromosomal deletions of between 1–10 Kb in size, inversions in
all size ranges, as well as short (=<10 Kb) and long (>1Mb)
tandem duplications (Fig. 5d). This combination of indel and
rearrangement patterns showed a high degree of similarity to
those seen in primary tumours with defects of other well-known
HR components such as BRCA1 and BRCA215,17.
To understand whether the targeting of these DNA repair
genes could affect proliferation, we measured the proliferation
rates of the given cell lines over a period of ten days
(Supplementary Fig. 1c). The MSH6, EXO1 and FANCC knock-
outs had the slowest proliferation rate, indicating that loss of
these genes is not associated with an increased proliferative rate.
Hence, the elevated numbers of mutations in MSH6, EXO1 and
FANCC knockouts were not simply due to an increase in the rate
of cell division. Based on these assays, the mutation rates of the
seven mutational signatures can be calculated: MSH6 knockout
signatures produced ~148 substitutions and ~36 indels per cell
division; EXO1 knockout signatures produced ~16 substitutions,
~0.58 indels and ~0.19 rearrangements per cell division; FANCC
knockout signatures produced ~0.58 indels and ~0.68 rearrange-
ments per cell division (Supplementary Data 4).
The knockouts of CHK248–50, NEIL151, NUDT152, POLB53,
POLE54 and POLM55 did not appear to produce detectable
mutational signatures under these experimental conditions.
Additionally, apart from the gene-edits themselves, there were
no additional recurrent activating mutations or loss-of-function
mutations identified in subclones after culture, suggesting that the
enrichment of “driver” events was not a feature in these
experiments.
Somatic mutations in DNA polymerase epsilon (POLE) have
been reported to be associated with a characteristic mutational
process in Signature 1056,57. We found however that knockout of
POLE, did not appear to be associated with a striking signature in
our study. This is not surprising, given that the identified
mutational signature is associated with mutations in the proof-
reading domain of POLE (dominant negative effect), which is not
mimicked by the knockout.
These results highlight successful, methodically-generated
genome-wide mutation patterns of all classes, in a human
cell-based system, demonstrating that biological abrogation of
some DNA repair genes not only initiates mutagenesis, but
Fig. 2 Schematic illustration of algorithm developed in the present study. a Schematic illustration distinguishing the mutational spectrum of parental clones
and subclones. Each red “+” represents a parent clone and green “+” represents a subclone. Red and green clouds represent bootstrapped samples for
parental clones and subclones respectively. dps is the distance between the centroid of parental clones and that of subclones. Red dashed circle shows the
boundary of distance dpc with p value= 0.01 and green dashed circle shows the boundary of distance dsc with p value= 0.01 (see online Methods). The
mutational spectra of parental clones and subclones are considered to be different only when dps > dpc_0.01 and dps > dsc_0.01. b Distribution of background
mutation number in subclones. Left: The number of mutations in each sample. Cyber yellow and grey highlight the samples that do not have or do have
mutational spectrum shifts from parental clones, respectively. Right: Mutation numbers of the samples that do not have mutational spectrum shifts (cyber
yellow samples) are used to construct a distribution indicating expected numbers of mutations in cells where the gene knockout does not have an effect. c
Workflow of characterisation on knockout signatures. d, e Detailed workflow of quantitative estimation of the difference between the mutation spectrum of
parental clones and that of subclones by bootstrapping parental clones (d) and subclones (e) (see Online Methods). f Detailed work flow of the
construction of the distribution of mutation numbers generated in cells where the gene knockout does not have an effect, using bootstrap sampling
methods (see Online Methods)
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creates distinctive mutation patterns, or mutational signatures,
conclusively validating the abstract concept of mutational
signatures in human cancers. Furthermore, single gene targeting
in vitro in some cases generated not just one but multiple
mutational signatures, buttressing previous reports that multiple
in vivo cancer-derived signatures could arise from single gene
defects such as in BRCA1/BRCA217. This is likely to be due to the
multitude of compensatory DSB repair pathways that are brought
into play in the absence of conservative, error-free HR and due to
some activity of translesion synthesis. Whatever are the
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mechanisms that underpin these observations, this is important
authentication—because multiple mutational signatures are now
starting to be exploited as a principle for designing clinical
biomarker assays17. This notion of using multiple signals as a
biomarker would predict more sensitive and more specific
tumour stratification—critical for clinical trials that are currently
still largely based on single-channel assays with all their attendant
limitations.
Similarities between experimental and cancer signatures. When
mutational signatures were first mathematically extracted from
cancers, several mutational signatures were found to be associated
with inactivation of DNA repair genes. To investigate how
in vitro experimentally-generated mutational signatures of gene
knockouts compared with in in vivo cancer-derived signatures,
we calculated cosine similarities between the in vivo and in vitro
mutational signatures for substitutions (Fig. 6a) and rearrange-
ments (Fig. 6b) (cancer-derived indel signatures are not avail-
able). Then, we compared overall mutational profiles of
knockouts with those of patient cancers.
The substitution signatures of MSH6 and EXO1 knockouts
were compared with cancer-derived 30 COSMIC signatures
(http://cancer.sanger.ac.uk/cosmic/signatures). The MSH6 knock-
out signature is most similar to COSMIC signature 20 with cosine
similarity of 0.91 (Fig. 6a), although there are relatively high
cosine similarities when compared to other cancer-derived
signatures associated with MMR-deficiency (all ⩾0.6). The
EXO1 knockout substitution signature is most similar to
COSMIC Signatures 3 (0.71) and 5 (0.71). Whole genome
profiles of experimentally-generated gene knockouts bear
uncanny resemblances to whole genome profiles of primarily
repair-deficient tumours (Fig. 6c). The MSH6 knockout, for
example, bears striking similarity to those in MMR-deficient
tumours—characterised by C>T and T<C substitution signatures
and high burden of indels at polynucleotide repeat tracts
(Supplementary Fig. 5). By contrast, the FANCC and EXO1
knockouts are more similar to HR-deficient cancers; defined by
general genomic instability and an excess of deletions with
microhomology at the breakpoint junction (Fig. 6c, Supplemen-
tary Figs. 6 and 7). This is an interesting observation because
although both of these proteins are not typical HR genes, they do
play a role in promoting HR repair of DNA double-strand breaks.
These data also provide additional experimental evidence to
support how cancers that are deemed to be “HR-deficient”, can be
sub-classified further genetically.
In a previous analytical exercise exploring structural variation
in breast cancer, six classes of rearrangement signatures were
identified15, including two types of tandem duplication signatures
—Rearrangement Signature 3 (RS3) comprising short (<10 Kb)
tandem duplications and enriched in BRCA1-null tumours and
Rearrangement Signature 1 (RS1) comprising long (>100 Kb)
tandem duplications, not associated with BRCA1 mutations
although a genetic cause has not been identified. The rearrange-
ment signatures of EXO1 and FANCC knockouts were compared
with cancer-derived rearrangement signatures (RS1-RS6). The
EXO1-knockout rearrangement signature is strikingly similar
(0.93) to RS1 which is defined by long tandem duplications
(Fig. 6b). By contrast, the FANCC-knockout rearrangement
signature shows little similarity (0.09) to RS1, and instead shows
elements of RS3 (0.43) and RS5 (0.59), which have short tandem
duplications and deletions. Hence, we show that these rearrange-
ment signatures are not just mathematical abstractions but indeed
separate biological entities—that is, the two tandem duplication
patterns, namely RS1 and RS3, are able to be recreated by
knocking out disparate genes. The FANCC knockout rearrange-
ment pattern comprised mainly short tandem duplications and
short deletions (<10 Kb) and also had other rearrangement classes
but essentially echoed those of BRCA1-null cancers (Fig. 6c and
Supplementary Fig. 6). This is consistent with the role played by
BRCA1 in HR, downstream of the FA pathway46,58. By contrast,
the EXO1 knockout rearrangement signature was dominated by
medium-to-long tandem duplications emulating the alternative
cohort of genomically unstable (but BRCA1-intact) tumours
(Fig. 6c and Supplementary Fig. 7).
Genomic architecture of experimentally-generated signatures.
Previous analyses of breast-cancer-derived mutational signatures
revealed diverse relationships with replicative strand and repli-
cative time domains, as well as transcriptional strands. We thus
explored whether experimentally-generated mutational signatures
mirrored are thereby validated these mathematically-derived
observations.
Of the experimentally-generated mutational signatures, first,
we did not find evidence of transcriptional strand bias (Fig. 7a
and Supplementary Fig. 8). Second, replication strand asymmetry
was not observed for the signatures caused by knockouts of
EXO1, though it was observed for the C>T/G>A (1.27 fold, p
value= 0.021, t test) and T>C/A>G (1.38, p value= 0.018, t test)
components of the MSH6 knockout (Fig. 7b). This interesting
bias was consistent with the observation that MMR deficiency
associated mutational signatures 6, 20 and 26 have either an
excess of damage to G and T on the lagging replicative strand or
C and A on the leading replicative strand (Fig. 7c). This implied
that MSH6 must have a particular role in directing the repair of
damage of these nucleotides during replication. Third, while
EXO1 knockout mutational signatures were consistently
increased in regions of the genome associated with late
replication, the mutational signature of MSH6 demonstrated a
Fig. 3 Determination of substitution mutational signatures in gene knockouts. a Profile of 96 mutation types (6 types of substitution ∗ 4 types of 5’ base ∗ 4
types of 3’ base) of parental clones and DNA repair gene knockouts. A strong background signature is observed in all samples. The substitution spectrum
of each sample is shown in Supplementary Fig. 2. Error bars were referred to as standard error of means (n= 7). b Discrimination of mutation spectrum of
parental clone and subclones. Bootstrap sampling method was used to construct a population of parental clones. The distribution of distance of parental
clone replicates to the centroid of parental clones is shown as the pink histogram. The red dashed line indicates a cutoff (dpc_0.01) where 99% replicates are
within this distance to the centroid of parental clones. The distribution of subclone replicates is shown as the light green histogram. The green dashed line
indicates a cutoff (dsc_0.01) where 99% subclones are within this distance to the centroid of all subclones. The blue arrow indicates the distance (dps)
between centroid of subclones to the centroid of parental clones. A knockout is considered to have an effect on the substitution spectrum, when dps >
dpc_0.01 and dps > dsc_0.01 are observed, e.g., EXO1, FANCC,MSH6. c Identification of mutation number increase in subclones due to gene knockout. From (b),
one can discriminate the knockouts that do not generate mutational signatures. The number of mutations in these knockout backgrounds can be used as a
baseline; through bootstrap sampling method, we obtained the distribution of the number of mutations in subclones in a wildtype background and,
therefore calculated the p value of mutation number of each knockout. EXO1 andMSH6 show significantly elevated mutation numbers as well as mutational
profile change. d Substitution signatures of EXO1 and MSH6 knockouts. The mutational signatures associated with gene knockouts are obtained by
removing the substitution profile of parental clones from the mean of the substitution spectrum of the seven subclones
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notably flatter slope, with more mutations early in replication
compared to the other knockout signatures (Fig. 7d). This
strikingly echoed in vivo observations—a base substitution
signature associated with tumour MMR deficiency also exhibits
a flattened profile across replication timing domains, unlike most
other substitution signatures in breast cancer13. Crucially, this
result from an experimentally-generated knockout of MSH6
provided support for a previous hypothesis that MMR activity is
essential for reducing mutagenesis in gene-rich, early replicative
domains. When abolished, the protective role usually played by
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MMR on mutagenesis in these regions, is lost, thus resulting in
the excess of mutations in early domains and a flattened
replication timing profile13. In conclusion, our findings collec-
tively show that mutational signature behaviours across genomic
architecture are corroborated by in vitro studies.
Discussion
The gene-edited human cell-based model system used here has
permitted validation of the mutational signatures concept across
all classes of mutations. This system, however, is not without
issues. A challenge posed by the considerable cell culture-related
signature resulted in an encumbered signal-to-noise ratio. Here,
we combine the experimental set-up with algorithmic develop-
ments in order to successfully view mutational patterns generated
by knockout of DNA repair genes. These principles lend them-
selves to a thorough, systematic screen of all genes involved in
maintaining genome integrity and of all potential genotoxic
agents in order to comprehensively understand the repertoire of
mutational signatures in human cells.
We found that in our experimental setup, not all knockouts of
genes associated with DNA repair produced detectable muta-
tional signatures. While this could reflect lack of a mutational
signature, it is also possible that some gene knockouts produce
signals that are too weak to be detected under these experimental
conditions. They require intensification through elevating muta-
tion rates. One way this could be achieved is by increasing
cumulative time in culture—but the data here already suggest that
mutation accumulation rates are variable between genes and a
one-size-fits-all approach will therefore always have its limita-
tions. Alternatively, increasing DNA damage experimentally
(using acute or chronic regimes) could help to amplify muta-
genesis. However, mutational signatures spawned through assis-
ted methods have arisen under subtly different conditions and
should be interpreted with this in mind. Using alternative iso-
genic models that are more permissive for mutagenesis (e.g.,
MEFs) could also help to increase mutation rates. However, using
different cell-based systems with different genetic backgrounds
could result in diverse mutational signatures, if similar studies are
performed. Lastly, because of the nature of growing cells in cul-
ture, it is possible that this is associated with some loss of insights.
Copy number changes are often poorly tolerated in cell-based
systems and copy number patterns may perhaps be under-
represented using these approaches.
Nevertheless, we present a proof-of-principle, demonstrating
how experimentally-generated mutation patterns recapitulate
those seen through analysis of primary tumours, thus authenti-
cating the abstract concept of mutational signatures. Our findings
also validate previously observed mutational signature relation-
ships with replication, both spatially and temporally. We also
note that our findings have also highlighted how a single gene
defect is not restricted to creating one mutational signature—it
can engender multiple mutational signatures of different classes.
The converse is also true: a mutational signature may not
necessarily reflect a defect in a single gene, as it could arise
through dysregulation of a number of related genes in a pathway.
Herein, we have conclusively demonstrated in vitro that endo-
genous mutational signatures are a direct, mechanistic read-out of
pathway dysfunction and could thus be used as biomarkers of
pathway dysregulation even in the absence of knowing the precise
gene defect or even which gene is compromised.
Methods
Culture conditions. HAP1 cells were grown in Iscove’s Modified Dulbecco’s
Medium (IMDM; GIBCO), containing L-Glutamine and 25 mM HEPES and
supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin
(P/S). Cells were grown at 37 °C, with 20% oxygen and 5% carbon dioxide.
HAP1 cells were passaged every 3 days and maintained sub-confluent for 1 month.
The cell lines were tested negative for mycoplasma contamination using MycoAlert
Mycoplasma Detection Kit. HAP1 is not listed in the database of commonly
misidentified cell lines by ICLAC. The parental HAP1 cell line has been
characterized and authenticated by our collaborators at Horizon Genomics.
Gene editing by CRISPR-Cas9. CRISPR-Cas9 knockouts were generated in
collaboration with Horizon Genomics. HAP1 cells were transfected with a Cas9
expressing plasmid, a guide RNA (gRNA) expressing plasmid and a plasmid
conferring Blasticidin resistance, using Xfect (Clontech). Guide RNA sequences
were 5′-AGGTAAAGCTGGCTTTCGAG-3′ (CHK2), 5′-ATCCATCAAATACG
AGAAT-3′ (EXO1), 5′-GCCAACAGTTGACCAATTGT-3′ (FANCC), 5′-CCAAG
ATGGAGGGTTACCCC-3′ (MSH6), 5′-TGCCCACCTGCGCTTTTACA-3′
(NEIL1), 5′-TTCGGGGCCGGCCGGTGGAA-3′ (NUDT1), 5′- GAGCAAACGGA
AGGCGCCGC-3′ (POLB), 5′-AGTTTCGGCACTCAAGCGCC-3′ (POLE), and
5′-ACAGGCCTGGCGCGCTCCAA-3′ (POLM).
Subsequently, the cells were treated with 20 μg/ml Blasticidin for 24 h in order
to eliminate untransfected cells. After 5–7 days of recovery from Blasticidin
selection, clonal cell lines were isolated by limiting dilutions.
Sanger sequencing. Genomic DNA was extracted using Viagen Bitoech
DirectPRC Lysis Reagent (Cell) adhering to the protocol provided by the
manufacturer. The genomic region targeted by the gRNA was amplified using the
primers and PCR amplification conditions provided below. Frameshift mutations
were identified using Nucleotide BLAST against the reference genome
GCF_000001405.33. Clones with frameshift mutations were selected as parental
cell lines.
Forward primers (For) were 5′-TCAAAGATGCCCCAAAATTTTCCAT-3′
(CHK2-For), 5′-CTCGTAAGTATCCAAGGCAGGATTT-3′ (EXO1-For), 5′-CA
AACCTACACACACATACATGGAC-3′ (FANCC-For), 5′-TGGCAGTAGTGAC
TCTTACCTGTAT-3′ (MSH6-For), 5′-TGGCCAGCCAGTTTGTGAAT-3′
(NEIL1-For), 5′-GCTGGGGAGTTACAGCATACC-3′ (NUDT1-For), 5′-ACTTG
TGAATAATTTTGTGTGGGTCA-3′ (POLB-For), 5′-CACTCTTTAGATAA
GGACCACGCTA-3′ (POLE-For) and 5′-TCGCCCTAATTAATAGCACCCTT
TA-3′ (POLM-For).
Reverse primers (Rev) were 5′-CTTTGTTTTTCCCTCTAGTGGTGC -3′
(CHK2-Rev), 5′-ATCATAGGGTACTAAGGTGCTGAAC-3′ (EXO1-Rev),
5′-ACTAAACAAGAAGCATTCACGTTCC-3′ (FANCC-Rev), 5′-AATGCCA
GAAGACTTGGAATTGTTT-3′ (MSH6-Rev), 5′-TGGTACTCCTGCAAGA
CACA-3′ (NEIL1-Rev), 5′-GAAACCAAGGGTGTGGCCCTA-3′ (NUDT1-Rev),
5′-CAGATCATAAGCTATGGAAGGGTGA-3′ (POLB-Rev), 5′-AGAGCAAGA
CTCCGTCTCAAAAA-3′ (POLE-Rev) and 5′-CGGAGTTTCCCTCTGCGTT-3′
(POLM-Rev).
PCR amplification: heat lid to 110 °C; start reaction with 94 °C for 2 min; loop
35 × (94 °C for 30 s; 55 °C for 30 s; 68 °C for 1 min), then finish with 68 °C for 7
min.
Fig. 4 Determination of indel signatures in gene knockouts. a Indel spectra of parental clones and DNA repair gene knockouts are represented by a 8-
channel indel profile which takes the type, length of indel motif and the characteristics at the indel junction into account: 1 bp insertion, >=2 bp insertion, 2
bp microhomology-mediated deletion, >=3 bp microhomology-mediated deletion, 1 bp repeat-mediated deletion, >=2 bp repeat-mediated deletion, other
deletions and complex indels. Error bars were referred to as standard error of means (n= 7). The indel spectrum of each sample is shown in
Supplementary Fig. 3. b Distribution of bootstrapped indel spectra of parental clone (pink) and subclones (green). FANCC, MSH6 and POLM show
significant changes in indel spectrums. c Comparison of indels numbers among subclones. The cyber yellow distribution is generated by bootstrapping the
indel number of knockout subclones without significant changes in indel profiles. EXO1, FANCC and MSH6 show significant increases in indel numbers,
indicating the effect of gene knockout on indels. In contrast, although POLM shows a detectable indel spectrum shift, it did not show a clear increase in
indel number (p value= 0.9966). Hence, POLM cannot be determined to have an indel signature. d Indel signature of EXO1, FANCC and MSH6. Indel
signature of EXO1 is similar to the culture indels signature. Indel signature of FANCC is dominated by microhomology-mediated deletions of 3 bp or more.
Indel signature of MSH6 is dominated by 1 bp deletions at poly-nucleotide repeat tracts
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Proliferation assay. Knockout cell lines were plated in triplicates at a density of
0.32 × 106 cells ml−1 and allowed to proliferate. Every second day, cells were dis-
sociated with Trypsin-EDTA (Gibco), living cells were counted using CASY Cell
Counter and Analyzer system (Innovatis), and replated at 1:2, 1:3 or 1:4 dilutions,
depending on the growth rate of the cell line. The experiment was carried out for
10 days. Proliferation was plotted for each time point considering the dilution rates.
The average growth rate is a mean over 10 days.
Protein extracts and immunoblotting. Cell extracts were prepared using RIPA
lysis buffer (NEB) with protease (Sigma) and phosphatase (Sigma) inhibitors.
Immunoblots were performed using standard procedures. Samples containing
proteins were separated using SDS PAGE 4–12% gradient gels (Invitrogen) and
transferred onto nitrocellulose membranes. The membranes were incubated with
primary and secondary antibodies. The primary antibodies were NUDT1 (NB100-
109, Novus Biologicals), CHK2 (05–649, Millipore), POLM (C1, Santa Cruz),
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EXO1 (A302-639A, Bethyl Laboratories), FANCC (MABC524- clone 8F3, Milli-
pore), POLE (GTX132100, GeneTex), Actin (A5060, SIGMA), NEIL1 (12145-1-
AP, Proteintech), POLB (ab26343, Abcam), and MSH6 (D60G2, Cell Signalling).
Catalogue numbers and working dilutions for antibodies are provided in Supple-
mentary Table 1. Uncropped immunoblot images are shown in Supplementary
Fig. 9.
DNA library preparation and sequencing. Five hundred nanogram of genomic
DNA was fragmented (average size distribution ~500 bp, LE220, Covaris Inc),
purified, libraries prepared (Agilent SureSelect XT custom kits, Agilent Technol-
ogies), and index tags applied (Sanger 168 tag set). Index tagged samples were
amplified (6 cycles of PCR, KAPA HiFi kit, KAPA Biosystems), quantified (dsDNA
BR assay, HS assay, Thermo Fisher Scientific), normalized (~0.85 ng/μl), then
pooled together in an equivolume fashion. Pooled samples were submitted to
cluster formation for HiSeq ×10 sequencing (32 lanes, 150 bp PE read length,
Illumina Inc). The average sequencing coverage is 15-fold for all samples given that
HAP1 is a haploid cell line. The details of sequence coverage for all clones and
subclones are provided in Supplementary Data 5.
Alignment and somatic variant-calling. Short reads were aligned to human
reference genome GRCh37/hg19. Somatic substitutions, indels and rearrangements
in clones and subclones were called by CaVEMan59 (http://cancerit.github.io/
CaVEMan/), Pindel60,61 (http://cancerit.github.io/cgpPindel) and BRASS15
(https://github.com/cancerit/BRASS), respectively.
De novo somatic mutations of substitutions, indels and rearrangements in
subclones were obtained by removing all mutations seen in parental clones. The
summary of de novo somatic mutations for each gene knockout is provided in
Supplementary Data 6.
Determination of mutational signatures for gene knockouts. The mutational
landscape of a cell over a certain period of time reflects a balance point between
DNA damage and repair processes in the cell. Exposure to exogenous mutagenic
agents or abrogation of DNA repair activity could affect this balance, thereby
inducing changes in the mutational landscape. Based on this principle, if the
knockout of a gene effectively generates a mutation pattern, then one could observe
two changes: First, a shift in the mutational spectrum of cells between subclones
and parental clones (shown schematically in Fig. 2a); Second, a change in numbers
of mutations in subclones when compared to background (Fig. 2b).
To conclusively identify an effect of a gene knockout, three steps are required:
(1) Detecting a qualitative difference between mutational spectra of knockout
subclones and that of parental clones; (2) Detecting a quantitative difference in
numbers of mutations. (3) Extracting knockout signature. Figure 2c demonstrates
the workflow. A more detailed method is described below.
In step 1, we applied a bootstrap resampling method on parental clones and
subclones, and calculated the Frobenius distance between parental clones and
subclones to quantify the difference between the mutational spectrum of parental
clone (without gene knockout effects) and that of subclones (with gene knockout
effects).
First, mutation profiles for parental clones (Mp) and subclones (Ms) for each
gene KO were defined as:
Mp ¼
m1p
..
.
mKp
2
664
3
775 and Ms ¼
m1s1    m1s7
..
. . .
. ..
.
mKs1    mKs7
2
664
3
775;
where m is the mutation number of each mutation feature in each sample, p and s
refer to the parental and subclones of different gene knockouts respectively.
The substitution spectrum is made up of a 96-channel vector (K= 96), where
for each of the six classes of C>A, C>G, C>T, T>A, T>C and T>G, the flanking 5′
and 3′ sequence context for each of the mutated bases is also taken into account (6
types of substitution ∗ 4 types of 5′ base ∗ 4 types of 3′ base= 96 channels). For
indels, the profiles are made up of eight features (K= 8), including 1 bp insertion,
>= 2 bp insertion, 2 bp microhomology-mediated deletion, >= 3 bp
microhomology-mediated deletion, 1 bp repeat-mediated deletion, >= 2 bp repeat-
mediated deletion, other type of deletion and complex indels, are used. For
rearrangements, ten mutation features (K= 10) are employed: 1–10 Kb, 10 Kb–1
Mb, and >1Mb sized deletions, inversions and tandem-duplications respectively
and translocations. The profile of substitutions, indels and rearrangements for all
samples are shown in Supplementary Figs. 2–4, respectively.
Second, a bootstrap distribution for parental clones was generated. Bootstrap
resampling was applied to each parental clone to generate 7000 replicates where the
frequency of each mutation type corresponded to its probability in the clone
multiplied by the total counts. In total, for nine parental clones, 63,000 replicates
are generated. From 63,000 replicates, seven samples are randomly selected and the
normalized distance between the centroid of the seven chosen replicates and the
centroid of original parental clones, is calculated as dpc. By repeating this step
10,000 times, we obtain a distribution of dpc (shown in Fig. 2d), and the distance
associated with p value= 0.01, dpc_0.01, is identified.
Third, bootstrap distributions for subclones of knockouts were generated. The
application of bootstrapping on subclones is similar to that of parental clones, see
Fig. 2e. For each knockout, 63,000 replicates of subclones are generated (9000
replicates * 7 subclones). Nine replicates are randomly chosen from 63,000
replicates and are used to calculate the normalized distance between the centroid of
replicates and the centroid of original subclones, dsc. The distribution of dsc is
therefore obtained by repeating the previous step for 10,000 times and the
threshold distance with p value= 0.01, dsc_0.01, can be calculated.
Finally, changes in mutational spectrum between parental clones and subclones
were determined. For each of the gene knockouts, the distance between centroid of
parental clones and centroid of subclones (dps) is compared with dpc_0.01 and
dsc_0.01. The criterion to determine whether the mutational spectrum associated
with a given gene knockout is significantly different to the parental clone is dps >
dpc_0.01 and dps > dsc_0.01, see Fig. 2a.
Step 2 involves determination of increase of mutation number associated with a
gene knockout. Aggregated mutation numbers of gene knockouts that do not have
a change in mutation spectrum (results from step 1) are used to construct a
distribution of baseline mutation counts (i.e., no effect of gene knockout), as shown
in Fig. 2f. According to this distribution, a p value of aggregated mutation number
of each gene knockout can be calculated. Gene knockouts with p value < 0.01 are
considered to have a significantly elevated mutation count, indicative of mutational
signatures associated with abrogation of these genes.
In step 3, we extracted knockout signatures based on quantile analysis. The
mutational spectrum of subclones can be seen as a linear combination of the
mutational spectrum present in parental clones (background mutagenesis) and the
mutational spectrum associated with the specific gene knockout:
Ms  ep ´Pp þ eko ´ Pko
where Pp ¼
P
p Mp=
P
p
P
k m
k
p and Ms is the centroid of seven subclones of each
knockout gene. ko refers to different gene knockouts. ep and eko are the number of
mutations caused by parental clone signature and knockout gene signature
respectively.
Hence, once a knockout gene is considered to have a mutational signature, its
signature (Pko) can be obtained by removing mutations associated with parental
clones from the mutation profile of the subclone:
Pko  ðMs  ep ´PpÞ=eko
The detailed steps are as described below:
First, we generated bootstrap distributions of subclones. For each knockout
gene, 10,000 replicates of subclones are generated to construct a distribution of
mutation number in kth of K features of each of the subclones. According to that
distribution, the upper and lower boundaries (99% CI) for each kth feature are
identified.
Second, the initial status is assumed that there is no knockout signature, i.e.,
background exposure, ep, is the total mutation number of subclones. Thus, the
background signature profile, ep ´ Pp , can be calculated. Each number in k
th of K
features of background signature profile was compared with the upper and lower
boundaries of each kth feature of subclones calculated from step 1. For each step,
Fig. 5 Determination of rearrangement signatures in gene knockouts. a The rearrangement spectra of parental clones and DNA repair gene knockouts are
represented by a 10-channel profile that takes the type and length of rearrangements into account. The rearrangement spectrum of each sample is shown
in Supplementary Fig. 4. Error bars were referred to as standard error of means (n= 7). b Distribution of bootstrapped rearrangement spectra of parental
clone (pink) and subclones (green) of the knockouts. EXO1, FANCC and NUDT1 knockouts show significant changes in their rearrangement profiles. c
Identification of elevated rearrangement numbers in knockouts. EXO1 and FANCC knockouts show high number of rearrangements (p value <= 0.01), while
NUDT1 has a p value of 0.0105, which is at the border of our threshold. To be conservative, NUDT1 is not determined to have a rearrangement signature. d
Rearrangement signature of EXO1 and FANCC. The rearrangement signature associated with knockout of EXO1 is characterised by median tandem
duplications (10 kb–1 Mb). The rearrangement signature associated with knockout of FANCC is characterised by short deletions (1–10 kb), deletions and
tandem duplications of 1–10 kb and 10 kb–1 Mb
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100 bootstrapping background exposure profiles are generated, and if there are at
least five parental signature profiles fall within the boundary of subclones, the
current background exposure is determined as the final background exposure, and
iteration stops. Otherwise, ep will reduce by 1 in the next step and the newly
constructed status will be compared with mutational profiles of subclones.
Third, once the background exposure, ep, is identified from step 2, the exposure
associated with a knockout is thus obtained by subtracting parental exposure from
centroid of subclones.
Topography of mutations associated with knockout genes. We explored the
relationships between genomic features, e.g., DNA replication and transcription,
and mutations associated with knockout genes. Reference information of replica-
tive strands and replication timing regions were obtained from the ENCODE
project Repli-seq data (https://www.encodeproject.org/)62. Regions of protein
coding gene in the genome were used to assign transcriptional strand coordinates.
Here, all substitutions are represented in pyrimidine context and the coordinates of
transcriptional and replicative strands are given on the +strand of the reference
genome, therefore the transcriptional/replicative strand information associated
with each substitution is adjusted to the pyrimidine-based mutation, e.g., a G>C
mutation on the transcribed strand is described as a C>G mutation on the non-
transcribed strand.
Code availability. The code for determination and extraction of knockout sig-
natures associated with this study is available from corresponding author (S.N.-Z.)
upon request.
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Fig. 6 Comparison of mutational signatures between cancer (in vivo) and knockouts (in vitro). a Cosine similarity between 30 COSMIC substitution signatures
(http://cancer.sanger.ac.uk/cosmic/signatures) and EXO1/MSH6 knockout substitution signatures. b Cosine similarity between six cancer-derived
rearrangement signatures and EXO1/FANCC knockout rearrangement signatures. c Genome plots ofMSH6, EXO1 and FANCC knockouts and of cancer samples.
Genome plots show somatic mutations including substitutions (outermost, dots represent six mutation types: C>A, blue; C>G, black; C>T, red; T>A, grey; T>C,
green; T>G, pink), indels (the second outer circle, colour bars represent five types of indels: complex, grey; insertion, green; deletion other, red; repeat-
mediated deletion, light red; microhomology-mediated deletion, dark red) and rearrangements (innermost, lines representing different types of
rearrangements: tandem duplications, green; deletions, orange; inversions, blue; translocations, grey). Genome plot of MSH6/EXO1/FANCC HAP1 knockouts
are aggregations of seven subclones. PD23564 and PD23579 are breast cancers with microsatellite instability which is resulted from impaired mismatch
repair. PD5956 and PD4841 are two breast cancers that would historically have been termed as having HR deficiency but are enriched for rearrangement
signature 1 and distinct from BRCA1/BRCA2-mutated cancers. PD11742 and PD9004 are two breast cancers with BRCA1/BRCA2-null HR deficiency
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04052-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1744 | DOI: 10.1038/s41467-018-04052-8 |www.nature.com/naturecommunications 13
Data availability. All mutation data can be obtained from: ftp://ftp.sanger.ac.uk/
pub/cancer/Zou_et_al_2017
All other remaining data are available within the Article and Supplementary
Files, or available from the authors upon request.
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Fig. 7 The topography of experimentally-generated mutations of EXO1, MSH6 and POLB knockouts. POLB does not show a mutational signature in
substitutions. It is shown here as a contrast against EXO1 andMSH6 signatures. The topography of mutational signatures associated with the remaining six
knockout genes is shown in Supplementary Fig. 8. a Histograms exploring transcriptional strand asymmetry. b Histograms exploring replication strand
asymmetry. c Histograms showing replicative strand asymmetry of mutational signatures in breast cancers. Twelve mutational signatures were identified
from 560 breast cancers15. Here only four signatures are shown: Signatures 6, 20 and 26 are associated with mismatch repair (MMR) deficiency; Signature
1 is associated with hydrolytic deamination of methylated CpG is shown as a contrast. d Distribution of normalized mutation density across the replication
timing domains. The G2/S phase was separated into ten replication timing domains13. Mutation densities in replication timing domains were corrected for
genomic size of each domain
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